Jacob Hooker

Last updated
Jacob Hooker
Hooker headshot.jpg
Alma mater North Carolina State University (BS)
University of California, Berkeley (PhD)
Known forDeveloped PET radiotracers for measuring biochemistry in the human brain
Awards Presidential Early Career Award for Scientists and Engineers (2010)
Scientific career
Fields Chemistry, neuroscience and drug development [1]
Institutions Harvard Medical School
Massachusetts General Hospital
Doctoral advisor Matthew Francis (Doctoral Advisor) [2]
Joanna Fowler (Postdoctoral Advisor) [3]

Jacob M. Hooker is an American chemist and expert in molecular imaging, specifically in the development and application of combined MRI and PET. He is the Lurie FamilyProfessor of Radiology specializing in Autism Research at Harvard Medical School. [4] He also serves as a Phyllis and Jerome Lyle Rappaport MGH Research Scholar, director of radiochemistry at the Martinos Center for Biomedical Imaging and scientific director at the Lurie Center for Autism at Massachusetts General Hospital. [5]

Contents

Life and education

He grew up outside of Asheville, North Carolina and attended Enka High School. Hooker received a B.S. in Textile Chemistry and Chemistry from North Carolina State University in 2002 and later earned a Ph.D. in Chemistry from the University of California, Berkeley [6] Hooker then completed postdoctoral training under the mentorship of Joanna Fowler at the Brookhaven National Laboratory, [7] as a Goldhaber Distinguished Fellow, developing new neuroscience-oriented imaging methods and protocols. [8]

Career

Hooker relocated to Boston,Massachusetts in 2009 at the initiation of his independent research career at the Martinos Center. [9] He co-designed and built a cyclotron and radiopharmacy facility housing a Siemens Eclipse HP Cyclotron, completed early 2011. [10] At Massachusetts General Hospital, Hooker co-founded and co-directs an imaging facility that combines functional MRI and positron emission tomography (PET) for the neurochemical study of the Human Brain. [11] He holds associate appointments at the Broad Institute and the Massachusetts Institute of Technology (MIT). [12] From 2017 to 2021, Hooker co-founded Eikonizo Therapeutics and later Sensorium Therapeutics. [13] He is also Editor-in-Chief of ACS Chemical Neuroscience. [14]

Hooker has been a Scientific Advisor for Delix Therapeutics, Psy Therapeutics, Inc., and Fuzionaire Diagnostics. [15] He is also chief science advisor to Rocket Science Health. [16]

Research

His research focus centers on the themes of neuroepigenetic, radiochemistry methods development and neuroimaging methods development, particularly leveraging positron emission tomography (PET). [17] [18] Hooker has published over 200 papers [19] in the domains of:

MR-PET: [11C]Martinostat uptake in living human brain. MSTAT.jpg
MR-PET: [11C]Martinostat uptake in living human brain.

PET Radiotracer Development

Hooker has developed PET radiotracers for measuring biochemistry in the human brain. [20] For example, in 2016, Hooker's team created the first detailed images of how certain brain enzymes, known as Class-I histone deacetylases (HDACs), function in living humans. [21] These enzymes play a key role in regulating genes and are linked to various brain disorders. By visualizing their activity, the research opened new doors to understanding how changes in these enzymes might contribute to conditions like schizophrenia, Alzheimer's disease, and autism, potentially leading to more targeted treatments. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32]

Radiochemistry

Hooker has made contributions to the advancement of radiochemistry methods for PET imaging. [33] [34] [35] For example, in 2011, Hooker collaborated with the Tobias Ritter lab to demonstrate the use of a palladium-IV complex in switching fluoride behavior in chemical reactions. This research was one of many other significant advances in radiochemistry and molecular imaging applications and decarboxylation with manganese catalysts. [36] [37]

Research on autism

As the scientific director of the Lurie Center for Autism at Massachusetts General Hospital, Hooker's work focuses on identifying specific subtypes of autism, which could pave the way for more precise diagnoses and treatments. [38] [39]

Neuroimaging methods

Hooker and his team were able to develop a method for brain glucose monitoring that produced something more like a movie, reporting changes in glucose use in response to multiple stimuli during a single PET scan. [40] The lab is now expanding the concept of dynamic, functional PET imaging to measure real-time neurotransmitter release in the living human brain. [41]

Other areas of exploration

At Harvard, Hooker's research lab, in collaboration with the Steve Haggarty lab, is exploring novel plant-based and entheogenic psychedelics, Their work includes projects such as investigating the potential of psychedelics in therapeutic applications. [42]

Recognition

In 2010, He received the Presidential Early Career Award for Scientists and Engineers. [43] [44] In 2016, Hooker was named as a Phyllis and Jerome Lyle Rappaport MGH Research Scholar which acknowledges 'forward thinking researchers with the funding they need to take their work into uncharted territories'. [45] In 2015, He was featured in the inaugural Talented 12 list by Chemical & Engineering News, for his work work in the area of molecular imaging, particularly focusing on positron emission tomography (PET). [46]

In 2015, the Brain & Behavior Research Foundation acknowledged Hooker with an Independent Investigator Award for research piloting neuroimaging in patients with Schizophrenia. [47] He was named by The Scientist magazine as a Scientist to Watch, [48] and in an article dubbing him 'The Mind Mapper' was among inaugural winners of the Talented 12 Award from the American Chemical Society's C & E News. [49] [50]

Hooker was named by the National Academy of Sciences as a Kavli Fellow for a five-year tenure (2012-2017) and as a Keck Futures Initiative Fellow (2013-2015). [51]

Related Research Articles

<span class="mw-page-title-main">Acetyl group</span> Chemical group, –C(=O)CH₃

In organic chemistry, an acetyl group is a functional group denoted by the chemical formula −COCH3 and the structure −C(=O)−CH3. It is sometimes represented by the symbol Ac. In IUPAC nomenclature, an acetyl group is called an ethanoylgroup.

<span class="mw-page-title-main">Histone deacetylase</span> Class of enzymes important in regulating DNA transcription

Histone deacetylases (EC 3.5.1.98, HDAC) are a class of enzymes that remove acetyl groups (O=C-CH3) from an ε-N-acetyl lysine amino acid on both histone and non-histone proteins. HDACs allow histones to wrap the DNA more tightly. This is important because DNA is wrapped around histones, and DNA expression is regulated by acetylation and de-acetylation. HDAC's action is opposite to that of histone acetyltransferase. HDAC proteins are now also called lysine deacetylases (KDAC), to describe their function rather than their target, which also includes non-histone proteins. In general, they suppress gene expression.

<span class="mw-page-title-main">Trichostatin A</span> Chemical compound

Trichostatin A (TSA) is an organic compound that serves as an antifungal antibiotic and selectively inhibits the class I and II mammalian histone deacetylase (HDAC) families of enzymes, but not class III HDACs. However, there are recent reports of the interactions of this molecule with Sirt 6 protein. TSA inhibits the eukaryotic cell cycle during the beginning of the growth stage. TSA can be used to alter gene expression by interfering with the removal of acetyl groups from histones and therefore altering the ability of DNA transcription factors to access the DNA molecules inside chromatin. It is a member of a larger class of histone deacetylase inhibitors that have a broad spectrum of epigenetic activities. Thus, TSA has some potential as an anti-cancer drug. One suggested mechanism is that TSA promotes the expression of apoptosis-related genes, leading to cancerous cells surviving at lower rates, thus slowing the progression of cancer. Other mechanisms may include the activity of HDIs to induce cell differentiation, thus acting to "mature" some of the de-differentiated cells found in tumors. HDIs have multiple effects on non-histone effector molecules, so the anti-cancer mechanisms are truly not understood at this time.

Vorinostat (rINN), also known as suberoylanilide hydroxamic acid, is a member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.

<span class="mw-page-title-main">Histone acetylation and deacetylation</span> Biological processes used in gene regulation

Histone acetylation and deacetylation are the processes by which the lysine residues within the N-terminal tail protruding from the histone core of the nucleosome are acetylated and deacetylated as part of gene regulation.

Histone deacetylase inhibitors are chemical compounds that inhibit histone deacetylases. Since deacetylation of histones produces transcriptionally silenced heterochromatin, HDIs can render chromatin more transcriptionally active and induce epigenomic changes.

<span class="mw-page-title-main">HDAC9</span> Protein-coding gene in the species Homo sapiens

Histone deacetylase 9 is an enzyme that in humans is encoded by the HDAC9 gene.

<span class="mw-page-title-main">HDAC7</span>

Histone deacetylase 7 is an enzyme that in humans is encoded by the HDAC7 gene.

<span class="mw-page-title-main">FOSB</span> Protein

Protein fosB, also known as FosB and G0/G1 switch regulatory protein 3 (G0S3), is a protein that in humans is encoded by the FBJ murine osteosarcoma viral oncogene homolog B (FOSB) gene.

<span class="mw-page-title-main">Romidepsin</span> Chemical compound

Romidepsin, sold under the brand name Istodax, is an anticancer agent used in cutaneous T-cell lymphoma (CTCL) and other peripheral T-cell lymphomas (PTCLs). Romidepsin is a natural product obtained from the bacterium Chromobacterium violaceum, and works by blocking enzymes known as histone deacetylases, thus inducing apoptosis. It is sometimes referred to as depsipeptide, after the class of molecules to which it belongs. Romidepsin is branded and owned by Gloucester Pharmaceuticals, a part of Celgene.

Autism spectrum disorder (ASD) refers to a variety of conditions typically identified by challenges with social skills, communication, speech, and repetitive sensory-motor behaviors. The 11th International Classification of Diseases (ICD-11), released in January 2021, characterizes ASD by the associated deficits in the ability to initiate and sustain two-way social communication and restricted or repetitive behavior unusual for the individual's age or situation. Although linked with early childhood, the symptoms can appear later as well. Symptoms can be detected before the age of two and experienced practitioners can give a reliable diagnosis by that age. However, official diagnosis may not occur until much older, even well into adulthood. There is a large degree of variation in how much support a person with ASD needs in day-to-day life. This can be classified by a further diagnosis of ASD level 1, level 2, or level 3. Of these, ASD level 3 describes people requiring very substantial support and who experience more severe symptoms. ASD-related deficits in nonverbal and verbal social skills can result in impediments in personal, family, social, educational, and occupational situations. This disorder tends to have a strong correlation with genetics along with other factors. More research is identifying ways in which epigenetics is linked to autism. Epigenetics generally refers to the ways in which chromatin structure is altered to affect gene expression. Mechanisms such as cytosine regulation and post-translational modifications of histones. Of the 215 genes contributing, to some extent in ASD, 42 have been found to be involved in epigenetic modification of gene expression. Some examples of ASD signs are specific or repeated behaviors, enhanced sensitivity to materials, being upset by changes in routine, appearing to show reduced interest in others, avoiding eye contact and limitations in social situations, as well as verbal communication. When social interaction becomes more important, some whose condition might have been overlooked suffer social and other exclusion and are more likely to have coexisting mental and physical conditions. Long-term problems include difficulties in daily living such as managing schedules, hypersensitivities, initiating and sustaining relationships, and maintaining jobs.

While the cellular and molecular mechanisms of learning and memory have long been a central focus of neuroscience, it is only in recent years that attention has turned to the epigenetic mechanisms behind the dynamic changes in gene transcription responsible for memory formation and maintenance. Epigenetic gene regulation often involves the physical marking of DNA or associated proteins to cause or allow long-lasting changes in gene activity. Epigenetic mechanisms such as DNA methylation and histone modifications have been shown to play an important role in learning and memory.

Cocaine addiction is the compulsive use of cocaine despite adverse consequences. It arises through epigenetic modification and transcriptional regulation of genes in the nucleus accumbens.

Epigenetic regulation of neurogenesis is the role that epigenetics plays in the regulation of neurogenesis.

<span class="mw-page-title-main">Epigenetic therapy</span> Use of epigenome-influencing techniques to treat medical conditions

Epigenetic therapy refers to the use of drugs or other interventions to modify gene expression patterns, potentially treating diseases by targeting epigenetic mechanisms such as DNA methylation and histone modifications.

Epigenetics of depression is the study of how epigenetics contribute to depression.

<span class="mw-page-title-main">Martinostat</span> Chemical compound

Martinostat is a histone deacetylase inhibitor (HDACi) that is potent against recombinant class I HDACs and class IIb HDAC with low nanomolar affinities. In tissue CETSA assays, martinostat exhibits selectivity for class I HDACs. When tagged with the radioisotope carbon-11, martinostat can be used to quantify HDAC in the brain and peripheral organs using positron emission tomography. Martinostat was given a name that adopted the style of other HDAC inhibitors, such as vorinostat, entinostat, and crebinostat, that recognized the academic center in which it was developed, the Martinos Center for Biomedical Imaging.

David E. Olson is an American chemist and neuroscientist. He is an associate professor of chemistry, biochemistry and molecular medicine at the University of California, Davis, and is the founding director of the UC Davis Institute for Psychedelics and Neurotherapeutics.

Neil Vasdev is a Canadian and American radiochemist and expert in nuclear medicine and molecular imaging, particularly in the application of PET. Radiotracers developed by the Vasdev Lab are in preclinical use worldwide, and many have been translated for first-in-human neuroimaging studies. He is the director and chief radiochemist of the Brain Health Imaging Centre and director of the Azrieli Centre for Neuro-Radiochemistry at the Centre for Addiction and Mental Health (CAMH). He is the Tier 1 Canada Research Chair in Radiochemistry and Nuclear Medicine, the endowed Azrieli Chair in Brain and Behaviour and Professor of Psychiatry at the University of Toronto. Vasdev has been featured on Global News, CTV, CNN, New York Times, Toronto Star and the Globe and Mail for his innovative research program.

References

  1. ↑ Zielgler, Carly (4 October 2021). "ACS Chemical Neuroscience Announces Professor Jacob Hooker as Editor-in-Chief". ACS Publications Chemistry Blog.
  2. ↑ "Matthew B. Francis Inventions, Patents and Patent Applications - Justia Patents Search". patents.justia.com.
  3. ↑ "Sensorium Jacob Hooker". www.sensorium.bio.
  4. ↑ Goldsmith, Paul (25 June 2024). "Autism and Old Age: Closing the Care Gap". Massachusetts General Hospital Giving.
  5. ↑ Bohonak, Jennifer Nejman (2021-11-08). "New Scientific Director Aims to Broaden Autism Research". Massachusetts General Hospital Giving. Retrieved 2024-07-29.
  6. ↑ "Jacob Hooker: Weaver of Brain Science". The Scientist Magazine®. Retrieved 2024-07-29.
  7. ↑ "Brookhaven Chemist Jacob Hooker Receives Presidential Early Career Award for Scientists and Engineers". Brookhaven National Laboratory. Retrieved 2024-07-29.
  8. ↑ Grant, Bob. "Jacob Hooker: Weaver of Brain Science". The Scientist. Retrieved 25 April 2016.
  9. ↑ "Brookhaven Chemist Jacob Hooker Receives Presidential Early Career Award for Scientists and Engineers". Brookhaven National Laboratory.
  10. ↑ "Jacob Hooker | Martinos Center". Martinos. 28 March 2019.
  11. ↑ Gilbert, Tonya M.; Zürcher, Nicole R.; Wu, Christine J.; Bhanot, Anisha; Hightower, Baileigh G.; Kim, Minhae; Albrecht, Daniel S.; Wey, Hsiao-Ying; Schroeder, Frederick A.; Rodriguez-Thompson, Anais; Morin, Thomas M.; Hart, Kamber L.; Pellegrini, Amelia M.; Riley, Misha M.; Wang, Changning; Stufflebeam, Steven M.; Haggarty, Stephen J.; Holt, Daphne J.; Loggia, Marco L.; Perlis, Roy H.; Brown, Hannah E.; Roffman, Joshua L.; Hooker, Jacob M. (2 January 2019). "PET neuroimaging reveals histone deacetylase dysregulation in schizophrenia". The Journal of Clinical Investigation. 129 (1): 364–372. doi:10.1172/JCI123743. ISSN   0021-9738. PMC   6307962 .
  12. ↑ "Jacob Hooker". Cure Alzheimer's Fund.
  13. ↑ "Sensorium Scores $30M to Change Risk-Value Proposition in CNS Drug Discovery". BioSpace. 7 November 2022.
  14. ↑ "Jacob Hooker appointed editor-in-chief of ACS Chemical Neuroscience". Knowledgespeak.
  15. ↑ "Jacob Hooker - Co-Founder at Sensorium Therapeutics". THE ORG.
  16. ↑ "Jacob Hooker | Chemical Biology PhD". chembiophd.hms.harvard.edu.
  17. ↑ Nonacs, Ruta; Rosenbaum, Jerrold (30 December 2021). "Jerrold Rosenbaum, MD: Toward a Better Understanding of How Psychedelics Work". MGH Psychiatry News.
  18. ↑ "Harvard Medical School professor discusses future of psychedelics". Harvard Gazette. 10 June 2021.
  19. ↑ Search Results for author Hooker JM on PubMed .
  20. ↑ Wey, Hsiao-Ying; Gilbert, Tonya M.; Zürcher, Nicole R.; She, Angela; Bhanot, Anisha; Taillon, Brendan D.; Schroeder, Fredrick A.; Wang, Changing; Haggarty, Stephen J.; Hooker, Jacob M. (2016). "Insights into neuroepigenetics through human histone deacetylase PET imaging". Science Translational Medicine. 8 (351): 351ra106. doi:10.1126/scitranslmed.aaf7551. PMC   5784409 . PMID   27510902.[ non-primary source needed ]
  21. ↑ Hooker, Jacob M.; Kim, Sung Won; Alexoff, David; Xu, Youwen; Shea, Colleen; Reid, Alicia; Volkow, Nora; Fowler, Joanna S. (2010). "Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography". ACS Chemical Neuroscience. 1 (1): 65–73. doi:10.1021/cn9000268. PMC   2908422 . PMID   20657706.[ non-primary source needed ]
  22. ↑ Wang, Changning; Eessalu, Thomas E.; Barth, Vanessa N.; Mitch, Charles H.; Wagner, Florence F.; Hong, Yijia; Neelamegam, Ramesh; Schroeder, Frederick A.; Holson, Edward B. (2013). "Design, synthesis, and evaluation of hydroxamic acid-based molecular probes for in vivo imaging of histone deacetylase (HDAC) in brain". American Journal of Nuclear Medicine and Molecular Imaging. 4 (1): 29–38. PMC   3867727 . PMID   24380043.
  23. ↑ Seo, Young Jun; Muench, Lisa; Reid, Alicia; Chen, Jinzhu; Kang, Yeona; Hooker, Jacob M.; Volkow, Nora D.; Fowler, Joanna S.; Kim, Sung Won (2013). "Radionuclide labeling and evaluation of candidate radioligands for PET imaging of histone deacetylase in the brain". Bioorganic & Medicinal Chemistry Letters. 23 (24): 6700–6705. doi:10.1016/j.bmcl.2013.10.038. PMC   4007514 . PMID   24210501.[ non-primary source needed ]
  24. ↑ Kim, Sung Won; Hooker, Jacob M.; Otto, Nicola; Win, Khaing; Muench, Lisa; Shea, Colleen; Carter, Pauline; King, Payton; Reid, Alicia E.; Volkow, Nora D.; Fowler, Joanna S. (2013). "Whole-body pharmacokinetics of HDAC inhibitor drugs, butyric acid, valproic acid and 4-phenylbutyric acid measured with carbon-11 labeled analogs by PET". Nuclear Medicine and Biology. 40 (7): 912–918. doi:10.1016/j.nucmedbio.2013.06.007. PMC   3769509 . PMID   23906667.[ non-primary source needed ]
  25. ↑ Schroeder, Frederick A.; Chonde, Daniel B.; Riley, Misha M.; Moseley, Christian K.; Granda, Michael L.; Wilson, Colin M.; Wagner, Florence F.; Zhang, Yan-Ling; Gale, Jennifer; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M. (2013). "FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors". Neuroscience Letters. 550: 119–124. doi:10.1016/j.neulet.2013.06.016. PMC   3750730 . PMID   23810801.[ non-primary source needed ]
  26. ↑ Wang, Yajie; Zhang, Yan-Ling; Hennig, Krista; Gale, Jennifer P.; Hong, Yijia; Cha, Anna; Riley, Misha; Wagner, Florence; Haggarty, Stephen J.; Holson, Edward; Hooker, Jacob (2013). "Class I HDAC imaging using [3H]CI-994 autoradiography". Epigenetics. 8 (7): 756–764. doi:10.4161/epi.25202. PMC   3781195 . PMID   23803584.[ non-primary source needed ]
  27. ↑ Schroeder, Frederick A.; Lewis, Michael C.; Fass, Daniel M.; Wagner, Florence F.; Zhang, Yan-Ling; Hennig, Krista M.; Gale, Jennifer; Zhao, Wen-Ning; Reis, Surya; Barker, Douglas D.; Berry-Scott, Erin; Kim, Sung Won; Clore, Elizabeth L.; Hooker, Jacob M.; Holson, Edward B.; Haggarty, Stephen J.; Petryshen, Tracey L. (2013). "A Selective HDAC 1/2 Inhibitor Modulates Chromatin and Gene Expression in Brain and Alters Mouse Behavior in Two Mood-Related Tests". PLOS ONE. 8 (8): e71323. Bibcode:2013PLoSO...871323S. doi: 10.1371/journal.pone.0071323 . PMC   3743770 . PMID   23967191.[ non-primary source needed ]
  28. ↑ Seo, Young Jun; Kang, Yeona; Muench, Lisa; Reid, Alicia; Caesar, Shannon; Jean, Logan; Wagner, Florence; Holson, Edward; Haggarty, Stephen J.; Weiss, Philipp; King, Payton; Carter, Pauline; Volkow, Nora D.; Fowler, Joanna S.; Hooker, Jacob M.; Kim, Sung Won (2014). "Image-Guided Synthesis Reveals Potent Blood-Brain Barrier Permeable Histone Deacetylase Inhibitors". ACS Chemical Neuroscience. 5 (7): 588–596. doi:10.1021/cn500021p. PMC   4102966 . PMID   24780082.[ non-primary source needed ]
  29. ↑ Wang, Changning; Schroeder, Frederick A.; Wey, Hsiao-Ying; Borra, Ronald; Wagner, Florence F.; Reis, Surya; Kim, Sung Won; Holson, Edward B.; Haggarty, Stephen J.; Hooker, Jacob M. (2014). "In Vivo Imaging of Histone Deacetylases (HDACs) in the Central Nervous System and Major Peripheral Organs". Journal of Medicinal Chemistry. 57 (19): 7999–8009. doi:10.1021/jm500872p. PMC   4191584 . PMID   25203558.[ non-primary source needed ]
  30. ↑ Schroeder, F. A.; Wang, C.; Van De Bittner, G. C.; Neelamegam, R.; Takakura, W. R.; Karunakaran, A.; Wey, H. Y.; Reis, S. A.; Gale, J.; Zhang, Y. L.; Holson, E. B.; Haggarty, S. J.; Hooker, J. M. (2014). "PET Imaging Demonstrates Histone Deacetylase Target Engagement and Clarifies Brain Penetrance of Known and Novel Small Molecule Inhibitors in Rat". ACS Chemical Neuroscience. 5 (10): 1055–1062. doi:10.1021/cn500162j. PMC   4198064 . PMID   25188794.[ non-primary source needed ]
  31. ↑ Wey, Hsiao-Ying; Wang, Changning; Schroeder, Frederick A.; Logan, Jean; Price, Julie C.; Hooker, Jacob M. (2015). "Kinetic Analysis and Quantification of [11C]Martinostat for in Vivo HDAC Imaging of the Brain". ACS Chemical Neuroscience. 6 (5): 708–715. doi:10.1021/acschemneuro.5b00066. PMC   4439341 . PMID   25768025.[ non-primary source needed ]
  32. ↑ Strebl, Martin G.; Wang, Changning; Schroeder, Frederick A.; Placzek, Michael S.; Wey, Hsiao-Ying; Van De Bittner, Genevieve C.; Neelamegam, Ramesh; Hooker, Jacob M. (2016). "Development of a Fluorinated Class-I HDAC Radiotracer Reveals Key Chemical Determinants of Brain Penetrance". ACS Chemical Neuroscience. 7 (5): 528–533. doi:10.1021/acschemneuro.5b00297. PMC   5784429 . PMID   26675505.[ non-primary source needed ]
  33. ↑ Lee, Eunsung; Kamlet, Adam S.; Powers, David C.; Neumann, Constanze N.; Boursalian, Gregory B.; Furuya, Takeru; Choi, Daniel C.; Hooker, Jacob M.; Ritter, Tobias (2011). "A Fluoride-Derived Electrophilic Late-Stage Fluorination Reagent for PET Imaging". Science. 334 (6056): 639–642. Bibcode:2011Sci...334..639L. doi:10.1126/science.1212625. PMC   3229297 . PMID   22053044.[ non-primary source needed ]
  34. ↑ Lee, Hong Geun; Milner, Phillip J.; Placzek, Michael S.; Buchwald, Stephen L.; Hooker, Jacob M. (2015). "Virtually Instantaneous, Room-Temperature [11C]-Cyanation Using Biaryl Phosphine Pd(0) Complexes". Journal of the American Chemical Society. 137 (2): 648–651. doi:10.1021/ja512115s. PMC   4394387 . PMID   25565277.[ non-primary source needed ]
  35. ↑ Huang, Xiongyi; Liu, Wei; Ren, Hong; Neelamegam, Ramesh; Hooker, Jacob M.; Groves, John T. (2014). "Late Stage Benzylic C–H Fluorination with [18F]Fluoride for PET Imaging". Journal of the American Chemical Society. 136 (19): 6842–6845. doi:10.1021/ja5039819. PMID   24766544.[ non-primary source needed ]
  36. ↑ Huang, Xiongyi; Liu, Wei; Hooker, Jacob M.; Groves, John T. (2015). "Targeted Fluorination with the Fluoride Ion by Manganese-Catalyzed Decarboxylation". Angewandte Chemie International Edition. 54 (17): 5241–5245. doi:10.1002/anie.201500399. PMID   25736895.[ non-primary source needed ]
  37. ↑ Neumann, Constanze N.; Hooker, Jacob M.; Ritter, Tobias (2016). "Concerted nucleophilic aromatic substitution with 19F− and 18F−". Nature. 534 (7607): 369–373. Bibcode:2016Natur.534..369N. doi:10.1038/nature17667. PMC   4911285 . PMID   27281221.[ non-primary source needed ]
  38. ↑ J. Freyer, Felice; November 22, Updated. "'It's a very human condition': Researchers seek answers to mystery of autism, in blood - The Boston Globe". BostonGlobe.com.{{cite web}}: CS1 maint: numeric names: authors list (link)
  39. ↑ Tseng, Chieh-En Jane; Canales, Camila; Marcus, Rachel E.; Parmar, Anjali J.; Hightower, Baileigh G.; Mullett, Jennifer E.; Makary, Meena M.; Tassone, Alison U.; Saro, Hannah K.; Townsend, Paige Hickey; Birtwell, Kirstin; Nowinski, Lisa; Thom, Robyn P.; Palumbo, Michelle L.; Keary, Christopher; Catana, Ciprian; McDougle, Christopher J.; Hooker, Jacob M.; Zürcher, Nicole R. (June 2024). "In vivo translocator protein in females with autism spectrum disorder: a pilot study". Neuropsychopharmacology. 49 (7): 1193–1201. doi:10.1038/s41386-024-01859-6. ISSN   1740-634X. PMC   11109261 .
  40. ↑ Villien, Marjorie; Wey, Hsiao-Ying; Mandeville, Joseph B.; Catana, Ciprian; Polimeni, Jonathan R.; Sander, Christin Y.; Zürcher, Nicole R.; Chonde, Daniel B.; Fowler, Joanna S.; Rosen, Bruce R.; Hooker, Jacob M. (2014). "Dynamic functional imaging of brain glucose utilization using fPET-FDG". NeuroImage. 100: 192–199. doi:10.1016/j.neuroimage.2014.06.025. PMC   4224310 . PMID   24936683.[ non-primary source needed ]
  41. ↑ Loggia, Marco L.; Chonde, Daniel B.; Akeju, Oluwaseun; Arabasz, Grae; Catana, Ciprian; Edwards, Robert R.; Hill, Elena; Hsu, Shirley; Izquierdo-Garcia, David; Ji, Ru-Rong; Riley, Misha; Wasan, Ajay D.; Zürcher, Nicole R.; Albrecht, Daniel S.; Vangel, Mark G.; Rosen, Bruce R.; Napadow, Vitaly; Hooker, Jacob M. (2015). "Evidence for brain glial activation in chronic pain patients". Brain. 138 (3): 604–615. doi:10.1093/brain/awu377. PMC   4339770 . PMID   25582579.[ non-primary source needed ]
  42. ↑ Weintraub, Karen. "Doctor hopes film raises awareness about adult autism - The Boston Globe". BostonGlobe.com.
  43. ↑ "Editor-in-Chief Jacob Hooker". ACS Publication.
  44. ↑ "DOE's Winners Since 1996 | U.S. DOE Office of Science (SC)". science.osti.gov. 2019-08-13. Retrieved 2024-02-29.
  45. ↑ "MGH Research Scholars 2016-2021". mgh research scholar.
  46. ↑ "C&EN's Talented 12". Chemical & Engineering News.
  47. ↑ "PET project: Imaging modality offers new insights into neurodegenerative disease | MGH/HST Martinos Center for Biomedical Imaging". www.nmr.mgh.harvard.edu.
  48. ↑ "Jacob Hooker: Weaver of Brain Science". The Scientist Magazine®.
  49. ↑ "Welcome talented12.cenmag.org - BlueHost.com". talented12.cenmag.org.
  50. ↑ Halford, Bethany (2015). "Jacob Hooker: The Mind Mapper". Chemical & Engineering News. 93 (27): 15. doi:10.1021/cen-09327-cover5.
  51. ↑ "'How big can I dream?' – Rappaport". Rappaport Foundation.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.